Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intra-Cellular Therapies Inc ITCI

Healthcare
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical... see more

Recent & Breaking News (NDAQ:ITCI)

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast

GlobeNewswire February 24, 2020

Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 21, 2020

Pivotal Study of CAPLYTA(TM) (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry

GlobeNewswire February 20, 2020

Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 18, 2020

Intra-Cellular Therapies Prices Public Offering of Common Stock

GlobeNewswire January 7, 2020

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

GlobeNewswire January 6, 2020

Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2020

FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults

GlobeNewswire December 23, 2019

Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology

GlobeNewswire December 12, 2019

Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology

GlobeNewswire December 4, 2019

Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results

GlobeNewswire November 5, 2019

Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast

GlobeNewswire October 29, 2019

Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 30, 2019

Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure

GlobeNewswire September 25, 2019

Intra-Cellular Therapies Provides Lumateperone Regulatory Update

GlobeNewswire September 10, 2019

Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results

GlobeNewswire August 7, 2019

Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference

GlobeNewswire August 6, 2019

Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA

GlobeNewswire August 5, 2019

Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia

GlobeNewswire July 23, 2019

Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression

GlobeNewswire July 8, 2019